These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2462084)

  • 1. [Potentialities of a cytomorphologic method in the evaluation of the efficacy of the treatment of cancer of the ovaries].
    Petrova S; Ali-zade VA
    Lab Delo; 1988; (10):31-5. PubMed ID: 2462084
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antitumor action of preparation No. 31 in malignant tumors of the ovaries (a clinical cytological study)].
    Kotova DG; Lipova VA
    Vopr Onkol; 1979; 25(3):24-7. PubMed ID: 373239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Initial treatment for ovarian cancer].
    Suzuki M; Fujiwara H; Takei Y
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):224-9. PubMed ID: 19263611
    [No Abstract]   [Full Text] [Related]  

  • 4. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
    Markman M
    Oncologist; 2007 Feb; 12(2):186-90. PubMed ID: 17296814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy].
    Bugat R; Guastalla JP; Misset JL
    Bull Cancer; 2005 Nov; 92(11):1003-6. PubMed ID: 16316835
    [No Abstract]   [Full Text] [Related]  

  • 6. Ovarian cancer: is dose intensity dead?
    Ozols RF
    J Clin Oncol; 2007 Sep; 25(27):4157-8. PubMed ID: 17698802
    [No Abstract]   [Full Text] [Related]  

  • 7. Investigational agents for epithelial ovarian cancer.
    Muggia F; Kosloff R
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current topic of intraperitoneal infusions for treatment of ovarian cancer].
    Fujiwara K
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):224-227. PubMed ID: 18372511
    [No Abstract]   [Full Text] [Related]  

  • 9. Phenoxodiol, a novel approach for the treatment of ovarian cancer.
    Mor G; Fu HH; Alvero AB
    Curr Opin Investig Drugs; 2006 Jun; 7(6):542-8. PubMed ID: 16784025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of ftorafur for the treatment of 3d-4th stage].
    Plaude RK; Osman VI; Tabachnik BI; Purinia IZh; Gutman EKh
    Vopr Onkol; 1975; 21(3):44-7. PubMed ID: 1093324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising new developments in the systemic treatment of ovarian cancer.
    Reed E
    J Assoc Acad Minor Phys; 1994; 5(1):16-21. PubMed ID: 7513218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of mono- and polychemotherapy in patients with advanced ovarian cancer].
    Khasanova DT; Kotova DG
    Vopr Onkol; 1984; 30(3):67-71. PubMed ID: 6369776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
    Pérez-López ME; Curiel T; Gómez JG; Jorge M
    Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CA-125 to assess response to new agents in ovarian cancer trials.
    Rustin GJ
    J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [1st experiences in the treatment of ovarian tumors with Peptichemio].
    Natale N; Mangioni C; Remotti G
    Minerva Med; 1974 May; 65(33):1805-10. PubMed ID: 4367233
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polyamines in the evaluation of the effectiveness of cancer patient treatment].
    Bassalyk LS; Nemtsova MP; Merabishvili NV; Tevzadze TA; Korbukh IA
    Vestn Akad Med Nauk SSSR; 1982; (3):57-61. PubMed ID: 6283759
    [No Abstract]   [Full Text] [Related]  

  • 18. Pros and cons for systemic therapy in recurrent ovarian cancer.
    Oskay-Ozcelik G; Sehouli J
    Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Second-line treatment using novel chemotherapeutic and biologic agents].
    Sugiyama T
    Gan To Kagaku Ryoho; 2009 May; 36(5):730-5. PubMed ID: 19461172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer and the battle of the specialists.
    McGuire WP
    J Clin Oncol; 2007 Aug; 25(23):3554-5; author reply 3557-8. PubMed ID: 17687166
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.